po construct forward outlook
report pretti ordinari link major ep beat/rais
come non-oper one-tim item came away encourag
three reason ibranc durabl intenational sale key growth driver beat
estimate driven strong volum uptak japan offset anticip
soften us sale us drug price management commentari assur us
drug price overhang dissip view confirm rel benign action
trump drug price blueprint catalyst re-rat recent
pharma discount broader shrunk near average
discount outright remov drug price overhang coupl continu
quarterli earn strength could push group closer averag discount
capit alloc call management left door open possibl divestitur and/or
 look ahead view tafamidi ttr transthyretin amyloidosi
import catalyst esc medic meet could drive sale upsid
our/consensu sale est preview note rais po base
higher eliqui sale forecast lower long-term tax rate outlook vs
unchang pe reiter buy rate
takeaway call
focu result us drug price work potu us
drug price blueprint allevi cost patient pos management believ
chang anti-kickback safe harbor may lead elimin drug rebat
frame elimin rebat posit compani said ceo
add caveat rebat could take time phase ibranc
breast cancer us growth slow management indic new
patient categori share deceler ibranc
hold share categori howev ex-u market ibranc beat our/street
est driven strong launch uptak major chang
messag focus pipelin asset compani note larg deal alway
avail necessari management field numer question new
corpor re-organ effect comment reorgan
could provid opportun look way simplifi busi structur
net dbt
solid sign overhang could
lift reiter buy po
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global biopharmaceut compani
diversifi portfolio product pipelin
candid one largest pharma
compani world measur market
capit revenu compon
jone industri averag compani
commerci oper bifurc two
busi segment innov ih
essenti eh gener
revenu total
view compani current valuat
undemand rel compani forward
ep growth face modest near-
term patent cliff encourag recent
event strengthen market leadership
key innov space offer attract
view sustain dividend
on-going strateg review consum busi
state intent engag post us tax
reform outcom could enhanc sharehold
billion
billion
million incom million incom million incom
billion
billion
billion
billion
billion
chart begun outperform broader market
perform measur present
chart continu trade pe multipl discount
histor ntm price-to-earnings rel drg
rel
rel drg
chart drg histor ntm price-to-earnings rel
drg rel
chart deal activ payment method mn
exclud joint invest deal undisclos size
chart deal activ type mn
exclud joint invest deal undisclos size
price object po base blend averag dcf forward price-to-earnings po
impli stock trade ep current
multipl consensu ep multipl base
regress analysi histor us major pharma forward month price-to-earnings multipl
year forward compound-annual-growth-rate ep believ dcf analysi base reason
assumpt includ modest sale growth cagr
respect reflect loss exclus lyrica viagra collect
account us sale forecast near-term headwind
off-set key growth brand xeljanz ibranc xtandi flat
sale growth follow downward rebas us sale pipelin
overal sale forecast out-year sale dcf assum
wacc tgr
risk sale downsid us sale continu declin and/or competit
take meaning market share ibranc could lead downsid estim
po inabl grow busi line forecast hold opex
spend flat level throughout forecast period transact
perceiv valu destruct dcf analysi reflect valu futur
 transact core element strategi
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
